Seizure: European Journal of Epilepsy
Volume 19, Issue 3 , Pages 185-189 , April 2010

Levetiracetam in the treatment of neonatal seizures: A pilot study

  • Alexandra Fürwentsches

      Affiliations

    • Department of Pediatric Neurology, University Children's Hospital, Heidelberg, Germany
    • Corresponding Author InformationCorresponding author at: Kinderheilkunde V, Pädiatrische Neurologie, Zentrum für Kinder- und Jugendmedizin, Im Neuenheimer Feld 430, 69120 Heidelberg, Germany. Tel.: +49 06221 56 38045; fax: +49 06221 56 5744.
    • ,
  • Cornelia Bussmann

      Affiliations

    • Department of Pediatric Neurology, University Children's Hospital, Heidelberg, Germany
    • ,
  • Georgia Ramantani

      Affiliations

    • Department of Pediatric Neurology, University Children's Hospital, Heidelberg, Germany
    • Department of Pediatric Neurology, University Children's Hospital, Dresden, Germany
    • ,
  • Friedrich Ebinger

      Affiliations

    • Department of Pediatric Neurology, University Children's Hospital, Heidelberg, Germany
    • ,
  • Heike Philippi

      Affiliations

    • Department of Pediatric Neurology, University Children's Hospital, Heidelberg, Germany
    • ,
  • Johannes Pöschl

      Affiliations

    • Department of Neonatology, University Children's Hospital, Heidelberg, Germany
    • ,
  • Susanne Schubert

      Affiliations

    • Department of Pediatric Neurology, University Children's Hospital, Heidelberg, Germany
    • ,
  • Dietz Rating

      Affiliations

    • Department of Pediatric Neurology, University Children's Hospital, Heidelberg, Germany
    • ,
  • Thomas Bast

      Affiliations

    • Department of Pediatric Neurology, University Children's Hospital, Heidelberg, Germany

Received 1 March 2009 ,Revised 5 January 2010 ,Accepted 7 January 2010.

References 

  1. Ronen GM, Penney S, Andrews W. The epidemiology of clinical neonatal seizures in Newfoundland: a population-based study. The Journal of Pediatrics. 1999;134(1):71–75
  2. Rennie JM, Boylan GB. Neonatal seizures and their treatment. Current Opinion in Neurology. 2003;16(2):177–181
  3. Bittigau P, Sifringer M, Ikonomidou C. Antiepileptic drugs and apoptosis in the developing brain. Annals of the New York Academy of Sciences. 2003;993:103–114
  4. Camfield CS, Chaplin S, Doyle AB, Shapiro SH, Cummings C, Camfield PR. Side effects of phenobarbital in toddlers. The Journal of Pediatrics. 1979;95:361–365
  5. Glauser TA, Ayala R, Elterman RD, Mitchell WG, Van Orman CB, Gauer LJ, et al. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology. 2006;66(11):1654–1660
  6. Angehagen M, Margineanu DG, Ben-Menachem E, Rönnbäck L, Hansson E, Klitgaard H. Levetiracetam reduces caffeine-induced Ca2+ transients and epileptiform potentials in hippocampal neurons. Neuroreport. 2003;14(3):471–475
  7. Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia. 2002;43(1):9–18
  8. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(26):9861–9866
  9. Rigo JM, Hans G, Nguyen L, Rocher V, Belachew S, Malgrange B, et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. British Journal of Pharmacology. 2002;136(5):659–672
  10. Glauser TA, Mitchell WG, Weinstock A, Bebin M, Chen D, Coupez R, et al. Pharmacokinetics of levetiracetam in infants and young children with epilepsy. Epilepsia. 2007;48(6):1117–1122
  11. Radtke RA. Pharmacokinetics of levetiracetam. Epilepsia. 2001;42(Suppl 4):24–27
  12. Privitera M. Efficacy of levetiracetam: a review of three pivotal clinical trials. Epilepsia. 2001;42(Suppl 4):31–35
  13. Opp J, Tuxhorn I, May T, Kluger G, Wiemer-Kruel A, Kurlemann G, et al. Levetiracetam in children with refractory epilepsy: a multicenter open label study in Germany. Seizure. 2005;14(7):476–484
  14. Manthey D, Asimiadou S, Stefovska V, Kaindl AM, Fassbender J, Ikonomidou C, et al. Sulthiame but not levetiracetam exerts neurotoxic effect in the developing rat brain. Experimental Neurology. 2005;193(2):497–503
  15. Hanon E, Klitgaard H. Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischemia. Seizure. 2001;10(4):287–293
  16. Löscher W, Hönack D, Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. The Journal of Pharmacology and Experimental Therapeutics. 1998;284(2):474–479
  17. Marini H, Costa C, Passaniti M, Esposito M, Campo GM, Ientile R, et al. Levetiracetam protects against kainic acid-induced toxicity. Life Sciences. 2004;74(10):1253–1264
  18. Trollmann R, Schneider J, Keller S, Strasser K, Wenzel D, Rascher W, et al. HIF-1-regulated vasoactive systems are differentially involved in acute hypoxic stress responses of the developing brain of newborn mice and are not affected by levetiracetam. Brain Research. 2008;1199:27–36
  19. Grosso S, Cordelli DM, Franzoni E, Coppola G, Capovilla G, Zamponi N, et al. Efficacy and safety of levetiracetam in infants and young children with refractory epilepsy. Seizure. 2007;16(4):345–350
  20. Grosso S, Franzoni E, Coppola G, Iannetti P, Verrotti A, Cordelli DM, et al. Efficacy and safety of levetiracetam: an add-on trial in children with refractory epilepsy. Seizure. 2005;14(4):248–253
  21. Perry MS, Benatar M. Efficacy and tolerability of levetiracetam in children younger than 4 years: a retrospective review. Epilepsia. 2007;48(6):1123–1127
  22. Mikati MA, El Banna D, Sinno D, Mroueh S. Response of infantile spasms to levetiracetam. Neurology. 2008;70(7):574–575
  23. Striano P, Coppola A, Pezzella M, Ciampa C, Specchio N, Ragona F, et al. An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. Neurology. 2007;69(3):250–254
  24. Goraya JS, Khurana DS, Valencia I, Melvin JJ, Cruz M, Legido A, et al. Intravenous levetiracetam in children with epilepsy. Pediatric Neurology. 2008;38(3):177–180
  25. Shoemaker MT, Rotenberg JS. Levetiracetam for the treatment of neonatal seizures. Journal of Child Neurology. 2007;22(1):95–98
  26. Mizrahi EM, Kellaway P. Characterization and classification of neonatal seizures. Neurology. 1987;37(12):1837–1844
  27. Painter MJ, Scher MS, Stein AD, Armatti S, Wang Z, Gardiner JC, et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. The New England Journal of Medicine. 1999;341(7):485–489
  28. Murray DM, Boylan GB, Ali I, Ryan CA, Murphy BP, Connolly S. Defining the gap between electrographic seizure burden, clinical expression and staff recognition of neonatal seizures. Archives of Disease in Childhood. Fetal and Neonatal Edition. 2008;93(3):F187–F191
  29. Booth D, Evans DJ. Anticonvulsants for neonates with seizures. Cochrane Database of Systematic Reviews. 2004;18(4):CD004218
  30. Scher MS, Alvin J, Gaus L, Minnigh B, Painter MJ. Uncoupling of EEG-clinical neonatal seizures after antiepileptic drug use. Pediatric Neurology. 2003;28(4):277–280

PII: S1059-1311(10)00004-X

doi: 10.1016/j.seizure.2010.01.003

Seizure: European Journal of Epilepsy
Volume 19, Issue 3 , Pages 185-189 , April 2010

Article Tools

* Image Usage & Resolution